4D PHARMA PLC ORD 0.25P: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei 4D PHARMA PLC ORD 0.25P listata cu simbolul UK.DDDD ==Descriere companie== 4D pharma plc (www.4dpharmaplc.com) is a United Kingdom-based pharmaceutical company that focuses on developing Live Biotherapeutic Products (LBPs), which is a drug derived from the human microbiome. The Company's LBPs are biologics based on live organisms, namely single strains of bacteria. It has developed its research to build MicroRx, which is a discovery platform that is...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| (Nu s-a afișat o versiune intermediară efectuată de același utilizator) | |||
| Linia 1: | Linia 1: | ||
Pagina dedicata companiei 4D PHARMA PLC ORD 0.25P listata cu simbolul UK.DDDD | Pagina dedicata companiei 4D [[PHARMA]] PLC ORD 0.25P listata cu simbolul UK.DDDD | ||
==Descriere companie== | ==Descriere companie== | ||
4D pharma plc (www.4dpharmaplc.com) is a United Kingdom-based pharmaceutical company that focuses on developing Live Biotherapeutic Products (LBPs), which is a drug derived from the human microbiome. The Company's LBPs are biologics based on live organisms, namely single strains of bacteria. It has developed its research to build MicroRx, which is a discovery platform that is able to select those bacteria that have a therapeutic effect in specific diseases. It uses MicroRx to interrogate its library of bacterial isolates to identify LBPs. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) disease. It is conducting a phase I/II clinical study of MRx-4DP0004 in patients with poorly controlled asthma. | 4D pharma plc (www.4dpharmaplc.com) is a United Kingdom-based pharmaceutical company that focuses on developing Live Biotherapeutic Products (LBPs), which is a drug derived from the human microbiome. The Company's LBPs are biologics based on live organisms, namely single strains of bacteria. It has developed its research to build MicroRx, which is a discovery platform that is able to [[SELECT|select]] those bacteria that have a therapeutic effect in specific diseases. It uses MicroRx to interrogate its library of bacterial isolates to identify LBPs. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and [[CENTRAL|central]] nervous system (CNS) disease. It is conducting a phase I/II clinical study of MRx-4DP0004 in patients with poorly controlled asthma. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
Versiunea curentă din 23 noiembrie 2024 12:53
Pagina dedicata companiei 4D PHARMA PLC ORD 0.25P listata cu simbolul UK.DDDD
Descriere companie[edit | ]
4D pharma plc (www.4dpharmaplc.com) is a United Kingdom-based pharmaceutical company that focuses on developing Live Biotherapeutic Products (LBPs), which is a drug derived from the human microbiome. The Company's LBPs are biologics based on live organisms, namely single strains of bacteria. It has developed its research to build MicroRx, which is a discovery platform that is able to select those bacteria that have a therapeutic effect in specific diseases. It uses MicroRx to interrogate its library of bacterial isolates to identify LBPs. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) disease. It is conducting a phase I/II clinical study of MRx-4DP0004 in patients with poorly controlled asthma.
Grafic actiuni companie[edit | ]